 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. Nasdaq: INFI Infinity or the Company, a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which has been shown to reverse a fundamental biologic mechanism of immune suppression in cancer and activate an anti-tumor immune response, today presents data updates from MARIO-275, the Companys randomized, placebo-controlled Phase 